3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
28
Lymphoma, Large B-Cell, Diffuse
21
Lymphoma
16
Multiple Myeloma
10
Lymphoma, Non-Hodgkin
10
Lymphoma, Follicular
8
Lymphoma, B-Cell
7
Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Burkitt Lymphoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms, Plasma Cell
4
Lymphoma, Mantle-Cell
4
Immunoblastic Lymphadenopathy
4
Recurrence
3
Lymphoma, T-Cell, Peripheral
3
Lymphoma, Primary Effusion
3
Lymphoma, Large-Cell, Anaplastic
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Plasmablastic Lymphoma
2
Neoplasm Metastasis
2
Myelodysplastic Syndromes
2
Metastatic Castration-resistant Prostate Cancer
2
Lymphoma, T-Cell
2
Hematologic Neoplasms
2
Enteropathy-Associated T-Cell Lymphoma
2
Interventions
Cyclophosphamide
5
fludarabine
3
fludarabine phosphate
2
Mesna
2
Antigens, CD19
2
navitoclax
1
ibrutinib
1
bempegaldesleukin
1
acalabrutinib
1
Vincristine
1
Stem Cell Transplantation
1
Rituximab
1
Prednisone
1
Nivolumab
1
Mycophenolic Acid
1
Melphalan
1
Lenalidomide
1
KW-2478
1
Interleukin-2
1
Hsp90 inhibitor KU757
1
Filgrastim
1
Doxorubicin
1
CTL019 chimeric antigen receptor
1
Bortezomib
1
Bone Marrow Transplantation
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Leukemia, B-Cell
×
Prednisone
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled